RE:RE:RE:Long termNice write up Dseng. Love that we can use some actual revenue projections to determine future share price potential.
For the 2019 medical Mj sales revenue I think using $400/patient per year is very conservative. If it is expected that each patient is worth $360 ebitda then the revenue generated per patient would be closer to $2000. So then the 50K patients are worth 100 milion in revenue. That would be assuming of course that they transfer the patients over to Cannmart and its not just referal revenue. If we use that number in the rest of your calculations the potential is enormous.
A lot still has to happen before we get anywhere near these numbers but it sure looks like we are on track to meet the year end targets. Looking forward to the 420 today, hopefully we get some more insight into the ICMD deal.